Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2

Exp Dermatol. 2017 Jan;26(1):89-92. doi: 10.1111/exd.13109. Epub 2016 Dec 20.

Authors

Mehdi Farshchian^{1

2}, Liisa Nissinen^{1

2}, Reidar Grénman³, Veli-Matti Kähäri^{1

2}

Affiliations

¹ Department of Dermatology, University of Turku and Turku University Hospital, Turku, Finland.
² MediCity Research Laboratory, University of Turku, Turku, Finland.
³ Department of Otorhinolaryngology - Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland.

PMID: 27305645
DOI: 10.1111/exd.13109

No abstract available

Keywords: ERK; EphB2; apoptosis; dasatinib; squamous cell carcinoma.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Apoptosis / drug effects
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / metabolism
Cell Line, Tumor
Dasatinib / pharmacology
Dasatinib / therapeutic use*
Drug Screening Assays, Antitumor
Humans
MAP Kinase Signaling System
Receptor, EphB2 / metabolism*
Skin Neoplasms / drug therapy*
Skin Neoplasms / metabolism

Substances

Antineoplastic Agents
EPHB2 protein, human
Receptor, EphB2
Dasatinib